238 related articles for article (PubMed ID: 35821174)
1. Using qualitative methods to establish the clinically meaningful threshold for treatment success in alopecia areata.
Wyrwich KW; Kitchen H; Knight S; Aldhouse NVJ; Macey J; Mesinkovska N; Ko JM; King BA
Qual Life Res; 2023 May; 32(5):1319-1327. PubMed ID: 35821174
[TBL] [Abstract][Full Text] [Related]
2. The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials.
Wyrwich KW; Kitchen H; Knight S; Aldhouse NVJ; Macey J; Nunes FP; Dutronc Y; Mesinkovska N; Ko JM; King BA
Br J Dermatol; 2020 Oct; 183(4):702-709. PubMed ID: 31970750
[TBL] [Abstract][Full Text] [Related]
3. Dermatologist and Patient Perceptions of Treatment Success in Alopecia Areata and Evaluation of Clinical Outcome Assessments in Japan.
Macey J; Kitchen H; Aldhouse NVJ; Burge RT; Edson-Heredia E; McCollam JS; Isaka Y; Torisu-Itakura H
Dermatol Ther (Heidelb); 2021 Apr; 11(2):433-447. PubMed ID: 33464474
[TBL] [Abstract][Full Text] [Related]
4. Development of the Scalp Hair Assessment PRO™ measure for alopecia areata.
Wyrwich KW; Kitchen H; Knight S; Aldhouse NVJ; Macey J; Nunes FP; Dutronc Y; Mesinkovska N; Ko JM; King BA
Br J Dermatol; 2020 Dec; 183(6):1065-1072. PubMed ID: 32163589
[TBL] [Abstract][Full Text] [Related]
5. A qualitative interview study to explore adolescents' experience of alopecia areata and the content validity of sign/symptom patient-reported outcome measures.
Macey J; Kitchen H; Aldhouse NVJ; Edson-Heredia E; Burge R; Prakash A; King BA; Mesinkovska N
Br J Dermatol; 2022 May; 186(5):849-860. PubMed ID: 34811721
[TBL] [Abstract][Full Text] [Related]
6. Analysis of alopecia areata surveys suggests a threshold for improved patient-reported outcomes.
Renert-Yuval Y; Correa da Rosa J; Garcet S; Pavel AB; Bares J; Chima M; Hawkes JE; Gilleaudeau P; Sullivan-Whalen M; Singer GK; Krueger JG; Guttman-Yassky E
Br J Dermatol; 2022 Oct; 187(4):539-547. PubMed ID: 35656793
[TBL] [Abstract][Full Text] [Related]
7. Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials.
Piraccini BM; Ohyama M; Craiglow B; Bewley A; Ding Y; Chen YF; Dutronc Y; Pierce E; Durand F; Mostaghimi A
J Dermatolog Treat; 2023 Dec; 34(1):2227299. PubMed ID: 37381691
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).
Kwon O; Senna MM; Sinclair R; Ito T; Dutronc Y; Lin CY; Yu G; Chiasserini C; McCollam J; Wu WS; King B
Am J Clin Dermatol; 2023 May; 24(3):443-451. PubMed ID: 36855020
[TBL] [Abstract][Full Text] [Related]
9. The Role of Patients in Alopecia Areata Endpoint Development: Understanding Physical Signs and Symptoms.
Wyrwich KW; Kitchen H; Knight S; Aldhouse NVJ; Macey J; Nunes F; Dutronc Y; Mesinkovska NA; Ko JM; King BA
J Investig Dermatol Symp Proc; 2020 Nov; 20(1):S71-S77. PubMed ID: 33099392
[TBL] [Abstract][Full Text] [Related]
10. The Alopecia Areata Severity and Morbidity Index (ASAMI) Study: Results From a Global Expert Consensus Exercise on Determinants of Alopecia Areata Severity.
; Moussa A; Bennett M; Wall D; Meah N; York K; Bokhari L; Asfour L; Rees H; Abraham LS; Asz-Sigall D; Basmanav FB; Bergfeld W; Betz RC; Bhoyrul B; Blume-Peytavi U; Callender V; Chitreddy V; Combalia A; Cotsarelis G; Craiglow B; Dhurat R; Donovan J; Doroshkevich A; Eisman S; Farrant P; Ferrando J; Gadzhigoroeva A; Green J; Grimalt R; Harries M; Hordinsky M; Irvine A; Jolliffe V; Kaiumov S; King B; Lee J; Lee WS; Li J; Lortkipanidze N; McMichael A; Mesinkovska NA; Messenger A; Mirmirani P; Olsen E; Orlow SJ; Ovcharenko Y; Piraccini BM; Pirmez R; Rakowska A; Reygagne P; Rudnicka L; Corralo DS; Senna M; Shapiro J; Sharma P; Siliuk T; Starace M; Suchonwanit P; Takwale A; Tosti A; Vañó-Galván S; Visser WI; Vogt A; Wade M; Yip L; Zhou C; Sinclair R
JAMA Dermatol; 2024 Mar; 160(3):341-350. PubMed ID: 38324292
[TBL] [Abstract][Full Text] [Related]
11. Estimation of health utility values for alopecia areata.
Aggio D; Dixon C; Law EH; Randall R; Price T; Lloyd A
Qual Life Res; 2024 Jun; 33(6):1581-1592. PubMed ID: 38551802
[TBL] [Abstract][Full Text] [Related]
12. When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials.
King B; Shapiro J; Ohyama M; Egeberg A; Piraccini BM; Craiglow B; Sinclair R; Chen YF; Wu WS; Ding Y; Somani N; Dutronc Y
Br J Dermatol; 2023 Nov; 189(6):666-673. PubMed ID: 37708254
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata: A Pooled Analysis of the BRAVE-AA1 and BRAVE-AA2 Trials.
Ko JM; Mayo TT; Bergfeld WF; Dutronc Y; Yu G; Ball SG; Somani N; Craiglow BG
JAMA Dermatol; 2023 Sep; 159(9):970-976. PubMed ID: 37556146
[TBL] [Abstract][Full Text] [Related]
14. Alopecia areata severity index (AASI): A reliable scoring system to assess the severity of alopecia areata on face and scalp-a pilot study.
Majid I; Sameem F; Sultan J; Aleem S
J Cosmet Dermatol; 2021 Aug; 20(8):2565-2570. PubMed ID: 34129730
[TBL] [Abstract][Full Text] [Related]
15. The effect of latanoprost 0.005% solution in the management of scalp alopecia areata, a randomized double-blind placebo-controlled trial.
Rafati M; Mahmoudian R; Golpour M; Kazeminejad A; Saeedi M; Nekoukar Z
Dermatol Ther; 2022 Jun; 35(6):e15450. PubMed ID: 35289043
[TBL] [Abstract][Full Text] [Related]
16. Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata.
Wyrwich KW; Kitchen H; Knight S; Aldhouse NVJ; Macey J; Nunes FP; Dutronc Y; Mesinkovska N; Ko JM; King BA
Am J Clin Dermatol; 2020 Oct; 21(5):725-732. PubMed ID: 32803546
[TBL] [Abstract][Full Text] [Related]
17. "'You lose your hair, what's the big deal?' I was so embarrassed, I was so self-conscious, I was so depressed:" a qualitative interview study to understand the psychosocial burden of alopecia areata.
Aldhouse NVJ; Kitchen H; Knight S; Macey J; Nunes FP; Dutronc Y; Mesinkovska N; Ko JM; King BA; Wyrwich KW
J Patient Rep Outcomes; 2020 Sep; 4(1):76. PubMed ID: 32914253
[TBL] [Abstract][Full Text] [Related]
18. Childhood Alopecia Areata: An Overview of Treatment and Recent Patents.
Hon KL; Luk DCK; Leung AKC; Ng C; Loo SKF
Recent Pat Inflamm Allergy Drug Discov; 2020; 14(2):117-132. PubMed ID: 32723274
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Effect of Superficial Cryotherapy on Alopecia Areata: A Prospective, Split-scalp Study in Patients with Multiple Alopecia Patches.
Jun M; Lee WS
Ann Dermatol; 2017 Dec; 29(6):722-727. PubMed ID: 29200760
[TBL] [Abstract][Full Text] [Related]
20. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
Almutairi N; Nour TM; Hussain NH
Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
